Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Vet Intern Med ; 32(4): 1383-1391, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29782043

RESUMO

BACKGROUND: Conventional fractionated radiotherapy has been shown to be partially effective for management of pituitary tumors in cats that cause acromegaly and diabetes mellitus (DM), but, the efficacy and safety of stereotactic radiation therapy (SRT) as a treatment for acromegalic cats has not been described. HYPOTHESIS: Stereotactic radiation therapy is an effective and safe treatment for controlling acromegaly associated with pituitary adenomas in cats. Additionally, SRT-treated acromegalic cats with DM will experience a decrease in insulin requirements after radiation therapy. ANIMALS: Fifty-three client-owned cats referred to Colorado State University for SRT to treat pituitary tumors causing poorly controlled DM secondary to acromegaly. METHODS: Retrospective study of cats treated for acromegaly with SRT between 2008 and 2016 at Colorado State University. Diagnosis of acromegaly was based on history, physical examination, laboratory results, and cross-sectional imaging of the pituitary. Signalment, radiation protocol, insulin requirements over time, adverse effects, and survival were recorded. RESULTS: Median survival time was 1072 days. Of the 41 cats for which insulin dosage information was available, 95% (39/41) experienced a decrease in required insulin dose, with 32% (13/41) achieving diabetic remission. Remission was permanent in 62% (8/13) and temporary in 38% (5/13) cats. Median duration to lowest insulin dose was 9.5 months. Of the treated cats, 14% developed hypothyroidism and required supplementation after SRT. CONCLUSIONS: Stereotactic radiation therapy is safe and effective for treating cats with acromegaly. Cats treated with SRT have improved survival time and control of their DM when compared to previously reported patients treated with non-SRT.


Assuntos
Adenoma/veterinária , Doenças do Gato/radioterapia , Adenoma Hipofisário Secretor de Hormônio do Crescimento/veterinária , Radiocirurgia/veterinária , Adenoma/diagnóstico por imagem , Adenoma/mortalidade , Adenoma/radioterapia , Animais , Doenças do Gato/diagnóstico por imagem , Doenças do Gato/mortalidade , Gatos , Feminino , Adenoma Hipofisário Secretor de Hormônio do Crescimento/diagnóstico por imagem , Adenoma Hipofisário Secretor de Hormônio do Crescimento/mortalidade , Adenoma Hipofisário Secretor de Hormônio do Crescimento/radioterapia , Masculino , Radiocirurgia/mortalidade , Estudos Retrospectivos , Análise de Sobrevida , Tomografia Computadorizada por Raios X/veterinária , Resultado do Tratamento
2.
J Vet Diagn Invest ; 29(6): 910-911, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28754087

RESUMO

Infections caused by methicillin-resistant Staphylococcus pseudintermedius (MRSP) can be challenging to treat because they are often resistant to many other antimicrobial agents. We assessed the susceptibility of 29 MRSP isolates from dogs to taurolidine in vitro. There was no growth at 0.12% taurolidine and light growth at 0.06% for all isolates. Taurolidine was reliable at inhibiting growth of MRSP at a concentration of 1,200 µg/mL.


Assuntos
Anti-Infecciosos/farmacologia , Doenças do Cão/microbiologia , Resistência a Meticilina , Infecções Estafilocócicas/veterinária , Staphylococcus/efeitos dos fármacos , Taurina/análogos & derivados , Tiadiazinas/farmacologia , Animais , Doenças do Cão/tratamento farmacológico , Cães , Testes de Sensibilidade Microbiana/veterinária , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/microbiologia , Taurina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA